MedTrace Logo

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

NCT05739292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-12-20

No results posted yet for this study

Summary

Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine

Conditions

  • Infection, Meningococcal

Interventions

BIOLOGICAL

EuNmCV-5

0.5mL single intramuscular dose on Day 0

BIOLOGICAL

Menveo

0.5mL single intramuscular dose on Day 0

Sponsors & Collaborators

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • YJ Choi · EuBiologics Co.,Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-05-10
Completion
2023-10-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739292 on ClinicalTrials.gov